Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine

Vaccine

Volumn 18, Issue 9-10, 1999, Pages 892-898

  Cederna, J B ^a,b   Klinzman, D ^a,b   Stapleton, J T ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cellular immunity; Hepatitis A virus; Vaccine

Indexed keywords

GAMMA INTERFERON; HEPATITIS A VACCINE; INACTIVATED VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HEPATITIS A; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE; VACCINATION;

ADULT; FEMALE; FORMALDEHYDE; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HEPATITIS ANTIBODIES; HUMANS; MALE; T-LYMPHOCYTES; VACCINES, INACTIVATED; VIRAL HEPATITIS VACCINES;

EID: 0032723985     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00342-4     Document Type: Article

References (38)

1. Miller M.J. Summary of current nomenclature, taxonomy and classification of various microbial agents. Clin. Infect. Dis. 16:1993;597-615.
2. Werzberger A., Mensch B., Kuter B., et al. A controlled trial of a formalin-inactivated hepatitis a vaccine in healthy children. N. Engl. J. Med. 327:1992;453-457.
3. Innis B.L., Snitbhan R., Kunasol P., et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 271:1994;1328-1334.
4. Lemon S.M., Stapleton J.T. Prevention of hepatitis A. Zuckerman A.J., Thomas H.C. Viral hepatitis. 1994;61-79 Churchill Livingstone, London.
5. Stapleton J.T., Lemon S.M. New vaccines against hepatitis A. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New generation vaccines. 1997;571-585 Marcel Dekker, Inc, New York.
6. Winokur P.L., Stapleton J.T. Immunoglobulin prophylaxis for hepatitis A. Clin. Infect. Dis. 14:1992;580-586.
7. Stapleton J.T., Jansen R., Lemon S.M. Neutralizing antibody to hepatitis A virus in immune serum gobulin and in the sera of human recipients of immune serum globulin. Gastroenterology. 89:1985;637-642.
8. Purcell R.H., D'Hondt E., Bradbury R., Emerson S.U., Govindarajan S., Binn L. Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine. 10:((Suppl. 1)):1992;S148-S151.
9. Katrak K., Mahon B.P., Minor P.D., Mills K.H.G. Cellular and humoral immune responses to poliovirus in mice: a role for helper T cells in heterotypic immunity to poliovirus. J. Gen. Virol. 72:1991;1093-1098.
10. Bottiger M. Antibody stimulation in individuals without demonstrable poliovirus antibodies following a fifth injection of inactivated poliovirus vaccine. Acta Pathol. Microbiol. Scand. B81:1973;795-798.
11. Salk D., Van Wezel A.L., Salk J. Induction of long-term immunity to paralytic poliomyelitis by use of noninfectious vaccine. Lancet. ii:1984;1317-1321.
12. Collen T., Pullen L., Doel T.R. T cell-dependent induction of antibody against foot and mouth disease virus in a mouse model. J. Gen. Virol. 70:1989;395-403.
13. Leclerc C., Deriaud E., Mimic V., Van der Werf S. Identification of a T cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1. J. Virol. 65:1991;711-718.
14. Francis M.J., Fry C.M., Rowlands D.J., et al. Immune response to uncoupled peptides of foot and mouth disease virus. Immunol. 61:1987;1-6.
15. Francis M.J., Hastings G.Z., Clarke B.E., et al. Neutralizing antibodies to all seven serotypes of foot and mouth disease virus elicited by synthetic peptides. Immunol. 69:1990;171-176.
16. Zachoval R., Gauss-Muller V., Abb J., Zachoval V., Deinhardt F. Lymphocyte stimulation by hepatitis A virus in vitro. Zuckerman A.J. Viral hepatitis and liver disease. 1988;65-66 Alan R. Liss, Inc, New York.
17. Zachoval R., Kroener M., Brommer M., Deinhardt F. Serology and interferon production during the early phase of acute hepatitis A. J. Infect. Dis. 161:1990;353-354.
18. Vallbracht A., Hofmann L., Wurster K.G., Flehmeg B. Persistent infection of human fibroblasts by hepatitis A virus. J. Gen. Virol. 65:1984;609-615.
19. Kurane I., Binn L.N., Bancroft W.H., Ennis F.A. Human lymphocyte responses to hepatitis A virus-infected cells: interferon production and lysis of infected cells. J. Immunol. 135:1985;2140-2144.
20. Stapleton J.T., Lemon S.M. Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus. J. Virol. 61:1987;491-498.
21. Ping L-H., Lemon S.M. Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies. J. Virol. 66:1992;2208-2216.
22. Winokur P.L., McLinden J.H., Stapleton J.T. The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into virus-like particles. J. Virol. 65:1991;5029-5036.
23. Stapleton J.T., Raina V., Winokur P.L., et al. Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles. J. Virol. 67:1993;1080-1085.
24. Johnston J.M., Harmon S.A., Binn L.N., Richards O.C., Ehrenfeld E., Summers D.F. Antigenic and immunogenic properties of a hepatitis A virus capsid protein expressed in Escherichia coli. J. Infect. Dis. 157:1988;1203-1211.
25. Powdrill T.F., Johnston J.M. Immunologic priming with recombinant hepatitis A virus proteins produced in E. coli. J. Virol. 65:1991;2686-2690.
26. Gauss-Muller V., Zhou M.Q., von der Helm K., Deinhardt F. Recombinant proteins VP1 and VP3 of hepatitis A virus prime for neutralizing response. J. Med. Virol. 31:1990;277-283.
27. McLinden J., Stapleton J., Rosen E. Anti-HAV neutralizing antibodies made to antigens produced by recombinant baculoviruses. Ginsberg H., Brown F., Lerner R.A., Chanock R. Modern approaches to new vaccines. Vaccines. 91:1991;239-244 Cold Spring Harbor Press, New York.
28. Harmon S.A., Broman B., Powdrill T.F., Johnston J.M., Ehrenfeld E., Summers D.F. Localization of priming epitope to the C-terminal portion of hepatitis A virus VP1. J. Infect. Dis. 167:1993;990-992.
29. Thomas M.P. Hepatitis A vaccination (Letter). N. Engl. J. Med. 339:1998;705-705.
30. Nalin D.R. Hepatitis A vaccination (Letter). N. Engl. J. Med. 339:1998;705-705.
31. Vallbracht A., Gabriel P., Maier K., Hartmann F., Flehmig B. Cell-mediated cytotoxicity in hepatitis A virus infection. Hepatology. 6:1986;1308-1314.
32. Wunschmann S., Vallbracht A., Flehmig B., Winokur P., Klinzman D., Stapleton J.T. Cytolytic T lymphocyte epitopes are present on hepatitis A virus structural proteins. Rizzeto M., Purcell R.H., Gerin J.L., Verme G. Viral hepatitis and liver disease. 1997;51-54 Edizioni Minerva Medica, Torino.
33. Gerety R.J., Smallwood L.A., Finlayson J.S., Tabor E. Standardization of the antibody to hepatitis A virus (anti-HAV) content of immunoglobulin. Develop. Biol. Standard. 54:1983;411-416.
34. Binn L.N., MacArthy P.O., Marchwicki R.H., et al. Laboratory tests and reference reagents employed in studies of inactivated hepatitis A vaccine. Vaccine. 10:((Suppl. 1)):1992;S102-S105.
35. Vallbracht A., Maier K., Stierhof Y.D., Wiedmann K.H., Flehmig B., Fleischer B. Liver-derived cytotoxic T cells in hepatitis A virus infection. J. Infect. Dis. 160:1989;209-217.
36. Rosenblum L.S., Villarino M.E., Nainan O.V., et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J. Infect. Dis. 164:1991;476-482.
37. Hadfield M.G., Seidlin M., Houff S.A., Adair C.F., Markowitz S.M., Straus S.E. Echovirus meningomyeloencephalitis with administration of intrathecal immunoglobulin. J. Neuropathol. Exp. Neurol. 44:1985;520-529.
38. Miller W.J., Clark W., Hurni W., Kuter B., Schofield T., Nalin D. Sensitive assays for hepatitis A antibodies. J. Med. Virol. 41:1993;201-204.